Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
MD, MBA. Professional experience in clinical research and at a top-tier management consulting firm, advising clients in the pharmaceutical and healthcare PE industry. Successfully invested in biotech for over a decade with a value-based approach
I share my portfolio, trades, and reasoning in real time with readers at my website: http://WisdomsReward.com (specifically look for the tab that says Value Focus)
My name is Chris McKinney. Wisdom's Reward is the name of a Christian investing website I started. My faith in Jesus Christ factors into my investing in various ways. The name "Wisdom's Reward" was suggested by a friend and comes from the fact that I started on the whole venture by studying Ecclesiastes and Proverbs (both are books of Wisdom) regarding what they had to say specifically about investing and finances, as well as other principles that could be applied to investing. In fact, there is a detailed report about that study available at my site.
My background: I used to work in the investment management industry, as a buy side Equity Trader, a Research Analyst, then a Senior Research Analyst in the Wealth Management group of a large commercial bank. Later, I worked as a Senior Investment Risk Analyst for an insurance company, as part of a team charged with managing that company's $60 billion portfolio. I had a great career going. Then my personal life got out of control, before I finally decided to surrender everything to a loving savior. He rescued me from myself, and my life is better today than I could have ever imagined it being. You can read more about that on my website.
My investment philosophy: Human beings cannot see the future, so we have to think in terms of probabilities, not certainties. Then we must examine the potential rewards under different scenarios to decide if something is attractively priced. It's easy to forget that we cannot see the future clearly. The more we study a particular topic, the more we can become convinced of a specific outcome. However, neither the future nor the market knows or cares how much study we put into something. We can increase our chances of getting things right. But, if we're wrong, the high probabilities we assigned to a certain scenario won't matter. All that will matter is what actually happened. So, risk management is incredibly important.
I've had lots of formal training and study. I believe the Mr. Market analogy used by Graham and Buffett to be the most important secular material I've ever read in regard to investments. Reading about cognitive biases and other mental errors, and then using that knowledge to guard against those things is also very important. Behavioral finance is probably the most useful area of study produced by scholars.
I am a start-up entrepreneur whose primary interest is in internet and technology stocks. I tend to hold positions in only a few stocks and hold on to them for some time. As Warren Buffet said "I am a better investor because I am a businessman and I am a better businessman because I am an investor"
Jason Hamlin is the founder of Gold Stock Bull and publishes a highly-rated investment newsletter focused on strategies for profiting in the bull markets in gold, silver, energy and agriculture. Mr. Hamlin has a background analyzing charts and trends for the world’s largest market research company, is versed in fundamental and technical analysis and has consulted to Fortune 500 companies around the globe. Jason is a cycles investor, student of Austrian economics and speaks regularly at investment conferences throughout North America. The Gold Stock Bull newsletter is focused on finding junior mining companies that are undervalued relative to their peers.
Richard Evans spent 26 years in the military, Business and Management as well as marketing within the retail, transportation, education and health care fields. He now lives in Las Vegas.
He writes extensively, having several hundred articles published on financial and travel topics as well as one guide book, with the help of two part time researchers.
His personal investment philosophy is "complicated."
He combines a selection of value/growth/dividend companies, in his best Warren Buffet imitation, along with a significant element to take advantage of arbitrage and other short term opportunities in the market.
Richard Evans concentrates on Energy companies, dividend opportunities, special opportunities and arbitrage, and because he does live in Las Vegas he keeps a weather eye on the Gaming Industry.
Awarded a 2015 & 2016 "Top 50 Financial Blogger" by TipRanks.com
- Ranked #44 out of 4,408 bloggers (#106 out of 8,174 overall experts) as of 8/18/15
- Ranked #37 out of 5,383 bloggers (#107 out of 9,507 overall experts) as of 8/18/16
- Follow my ongoing coverage on TerraVia (TVIA): http://seekingalpha.com/articles?filters=tvia,kevin-quon
Spear Point is a private equity firm that specializes in transaction oriented activist strategies in undervalued micro, smid-cap publicly traded companies.
I trade all kinds of situations, but love to get as many factors on my side as possible for a trade, including others possibly being out of position or incorrectly interpreting a situation, favorable macro drivers, favorably shifting fundamentals, and being able to hold winning trades longer than others seem capable of doing.
At this point in my short financial career, I've already developed a lot of confidence in my trading process.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
I am an individual investor with over 15 years experience in the stock and options markets. I focus on the precious metals, energy, and tech sectors. I believe that there are always opportunities in any kind of market, and I actively look for strategies to take advantage of these opportunities. My long-term outlook is that stock and commodity prices will go higher, and bond prices will go lower. Some of the investing principles that I follow include (1) taking what the market gives you, (2) investing where you have a competitive advantage, (3) having a plan in case a stock goes up or down, and (4) investing only when the odds are in your favor.
I am a retired wall street attorney. I started out specializing exclusively in securities law. As I developed my practice, it morphed into a corporate finance practice specializing in mergers and acquisitions, with the securities law aspects being secondary.
I'm not much for diversification. I tend to put a substantial amount in a few baskets and then watch those baskets very, very carefully.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Brian Marckx, CFA is the Senior Medical Device / Diagnostics Analyst with Zacks Investment Research. I cover small and micro-cap medical device and diagnostic companies. Focus is development-stage companies with novel and emerging technologies as well as already established names still flying under the radar.
Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks.
Brian has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. Brian is also a Chartered Financial Analyst charterholder.
I have worked in the healthcare sector for over 10 years. I have a background in statistical analysis as well as biology. I have developed a system designed to uncover a company's true value. I primarily research and trade stocks in the biotech sector. My investment strategy is simple, research a company from all angles to determine it's worth. I buy undervalued stocks and hold until my target price is reached. I have benefited from articles on SA and I hope to offer some the same value in my articles.
Ian Wyatt is an active investor, a well-regarded investment expert and an Internet entrepreneur. He is the Chief Investment Strategist at Wyatt Investment Research, and plays a leading role in each of the company’s investment newsletters and trading services.As a well-regarded market expert, Ian has written for Marketwatch, Zacks Investment Research, Seeking Alpha, Yahoo! Finance and The Burlington Free Press. He has been interviewed or quoted in articles in well-known publications including AOL Finance Blogging Stocks, Kiplinger’s Personal Finance Magazine, Barron Magazine, Barrons.com, Forbes.com, The Dick Davis Digest, The Dick Davis Income Digest, The Wall Street Transcript, TheStockAdvisors.com, Money Show Digest, The New Jersey Star Ledger, The Wisconsin State Journal and The Seattle Times.
In 1998, Ian combined two of his passions, stocks and the Internet, with the launch of a free investment web site with expert advice about investing in stocks.
Ian founded Business Financial Publishing and Wyatt Investment Research in 2001, publishing investment newsletters for individual investors. Since then, the company has evolved into an Internet content company publishing e-letters, special reports, newsletters, trading services and financial web sites.
Business Financial Publishing was named #185 on the 2008 Inc. Magazine Inc. 500 list of the fastest growing companies in the United States, achieving a 3-year growth rate of 1,303%. The company currently reaches over one million individual investors weekly through its free e-letters.
His first book, The Small-Cap Investor: Secrets to Winning Big with Small-Cap Stocks, was published by John Wiley & Sons in September 2009. Ian lives in the Green Mountains of Vermont with his wife Carrie.
I have a PhD in political science and have been investing for well over a decade. I generally follow small cap biotechnology, MLPs, and mining companies. I hope to provide my thoughts on both topics of interest to investors and particular companies.
See all of my reports at www.sobekanalytics.com
Follow me on twitter: @dsobek.
I am a semi-retired investor mainly trading equities & bonds. Most of my career was spent as an investment analyst in the front office of a private banking house In Geneva. Prior to that I worked for the Emerging Markets desk of a major banking house in London. Now that I'm retired, I write mainly about my lifelong interest, which is science and biology. I now live in Cyprus, on the periphery of the EU taking up the financial chaos from all sides.
I am a real estate developer and worked on dozens of projects over the last 20 years. I am also a market enthusiast enjoy trading companies in sevice sector, media and medical sectors.
I graduated Baruch College with a BBA in 1976.
I am a market enthusiast and part-time trader. I started writing for Seeking Alpha in 2011, and it has been a tremendous opportunity and learning experience. I have been interested in the markets since elementary school, and hope to pursue a career in the investment management industry. I have been active in the markets for several years, and am primarily focused on long/short equities.
I hold a Bachelor of Science Degree from Lehigh University, where I double majored in Finance and Accounting, with a minor in History. My major track focused on Investments and Financial Analysis. While at Lehigh, I was the Head Portfolio Manager of the Investment Management Group, a student group that manages three portfolios, one long/short and two long only. I have had two internships, one a summer internship at a large bank, and another helping to manage the Lehigh University Endowment for nearly a year.
Disclaimer: Bill reminds investors to always due their own due diligence on any investment, and to consult their own financial adviser or representative when necessary. Any material provided is intended as general information only, and should not be considered or relied upon as a formal investment recommendation.
David Fry writes a subscription newsletter focused on technical analysis of exchange-traded funds, called ETF Digest (www.etfdigest.com). Dave founded the ETF Digest in 2001 and was among the very first to see the need for a publication that provided individual investors with information and actionable advice on global ETF investing.
We particularly like the overview of financial markets that his work provides. Even if you're not a fan of chart analysis, Dave provides insight and commentary into which global markets are "working" and why.
Specializing as a market strategist and tactician, Fry focuses on evaluating, creating and implementing a variety of ETF portfolios for individual investors and financial professionals. His philosophy and approach incorporates fundamental with technical analysis in pursuit of risk management and capital preservation especially during uncertain and volatile times.
His new eBook, The Best ETFs: U.S. Equities,is now available on Amazon Kindle. Written as a cheat sheet to only the best ETFs for you or your client’s portfolios. For those that don't have a Kindle, you can purchase the pdf here: The Best ETFs: US Equities [https://gumroad.com/l/The%20Best%20ETFs]
I am a former hedge fund portfolio manager that trades for my own personal account. I espouse Graham and Dodd/Buffett style investing, always on the lookout for value equities or bonds. A graduate of Northwestern's Kellogg School of Management, I lived in NYC for a decade before relocating with my family to the Charlotte, NC area in 2007.
Currently I am the Chief Analyst at sharpeequities.com.
For more information on my current endeavor, feel free to find me on LinkedIn.
Jeffrey Dow Jones is the managing editor for Alpine Advisor. He has previously worked for PaineWebber/UBS and Ford Motor Credit Company, and he spent the last decade co-managing a group of hedge funds. He holds a degree in Business Economics with a specialization in Computer Programming from The University of California - Los Angeles.
He publishes a free weekly newsletter at AlpineAdvisor.info.
Analyst and Fund Manager with almost 20 years investment experience. Coverage includes a variety of industries, with a focus on technology.
Particularly focused on value stocks, poorly understood or under-followed situations, and contrarian perspectives.
Primarily invest in special situations with value that is poorly understood or not fully appreciated, or where we believe there is a highly asymetric risk/reward profile. Also look for long/short ideas in mid/larger cap names where we believe we have a variant view, and the market is dramatically mispricing value.
Follow me on Twitter @valinsights
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump.
Thomas has co-authored a book (The Intelligent REIT Investor) that is available on Amazon.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com